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Abstract
Introduction: Influenza vaccination is the primary strategy for prevention of influenza infection.
Influenza infection can vary from mild or even asymptomatic illness to severe community-acquired
pneumonia (CAP). Although many national and international investigators and organizations report
annual estimates of influenza vaccine effectiveness for prevention of influenza infection in the
community, few studies report estimates for the prevention of hospitalizations due to influenza CAP,
the most severe form of the infection. The objective of this study is to determine the effectiveness
of the influenza vaccine for prevention of hospitalization in patients with influenza-associated CAP.
Methods: This was a test-negative study using data from the first two years of the University of
Louisville Pneumonia Study, a prospective, observational study of all hospitalized patients with
pneumonia in Louisville, Kentucky from 6/1/2014 – 5/31/2016. Univariate and multivariate logistic
models were used to evaluate the association between vaccine status and influenza-associated/noninfluenza-associated CAP hospitalization. Unadjusted and adjusted vaccine effectiveness estimates
were calculated.
Results: A total of 1951 hospitalized patients with CAP were included in the analysis, and 831 (43%)
reported having received the influenza vaccination for the influenza season by the time they were
hospitalized. A total of 152 (8%) cases of influenza-CAP were confirmed in the study population, with
63 (8%) cases confirmed in vaccinated individuals. The unadjusted vaccine effectiveness was not
significant, with a point estimate of 5% (95% CI: -33%, 32%). After adjusting for potential cofounders,
vaccine effectiveness was also found to not be significant with a point estimate of 8% (95% CI: -30%,
35%).
Conclusions: In conclusion, we found that, over the 2014/2015 and 2015/2016 influenza seasons,
influenza vaccine was not effective for prevention of hospitalization with CAP due to influenza. More
effective vaccines are necessary to prevent the most serious forms of influenza.
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Introduction
Influenza vaccination is the primary strategy for prevention of
influenza infection, with the United States Advisory Committee
on Immunization Practices (ACIP) recommending vaccination
for individuals ages 6 months and older [1, 2]. Influenza
infection can vary from mild or even asymptomatic illness to
severe community-acquired pneumonia (CAP) [3]. Although
most individuals recover from influenza infection, young
children, older adults, and individuals with other chronic
medical conditions may experience more serious illness and
increased mortality [4-6].
Due to rapid mutations and other variations in influenza viruses
year to year around the world, annual vaccination is necessary
to provide immunologic protection from infection. Even in the
absence of direct matches between the circulating influenza
viruses and the antigens included in the vaccine, it is thought
that a reduction in severity may be conferred through the
vaccination [7-9]. Due to these factors, it is of medical and
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public health interest to understand the effectiveness of the
vaccine each season for prevention of various outcomes.
Vaccine effectiveness, not be confused with vaccine efficacy,
is a clinical approach to determining how effective a vaccine
is in reducing a disease in a real-life population. Although
there are several study designs to assess vaccine effectiveness,
retrospective case-control analysis of vaccination rates are
commonly employed. Vaccine efficacy is primarily measured
in prospective, randomized clinical trials. These trials involve
selected populations that may not be generalizable to the
population at large [10].
Although many national and international investigators and
organizations report annual estimates of influenza vaccine
effectiveness for prevention of influenza infection in the
community, few studies report estimates for the prevention of
hospitalizations due to influenza-CAP, the most severe form of
the infection [11-13].
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The objective of this study is to determine the effectiveness
of the influenza vaccine for prevention of hospitalization in
patients with influenza-CAP and to determine how well the
estimated effectiveness in the general population estimates the
effectiveness in hospitalized patients with CAP.

Methods
Study Design & Study Patients: This was a test-negative study
using data from the first two years of the University of Louisville
Pneumonia Study, a prospective, observational study of all
hospitalized patients with pneumonia in Louisville, Kentucky
from 6/1/2014 – 5/31/2016 [14].
Subjects: Patients were only eligible for inclusion in this analysis
if they 1) were hospitalized during the influenza season in each
study year (January, February, March, October, November,
December), and 2) had a reverse-transcriptase polymerase
chain reaction (RT-PCR) and/or rapid influenza diagnostic
testing (RIDT) performed during hospitalization. Patients
were considered vaccinated if they self-reported receiving any
influenza vaccination for that influenza season prior to their
hospitalization.
Study Definitions and Measurements: CommunityAcquired Pneumonia (CAP): A patient was defined as
having CAP when the following 3 criteria were met: 1) presence
of a new pulmonary infiltrate on chest radiograph and/or chest
computed tomography scan at the time of hospitalization,
defined by a attending radiologist’s reading; 2) at least 1 of
the following: a) new cough or increased cough or sputum
production, b) fever >37.8°C (100.0°F) or hypothermia <35.6°C
(96.0°F), c) changes in leukocyte count (leukocytosis: >11,000
cells/μL; left shift: >10% band forms/mL; or leukopenia: <4000
cells/μL); and 3) no alternative diagnosis at the time of hospital
discharge that justified the presence of criteria 1 and 2 [14].
Hospitalization with influenza-CAP: A hospitalized patient
with CAP testing positive for an influenza virus of any subtype
using Reverse Transcriptase-Polymerase Chain Reaction (RTPCR) or Rapid Influenza Diagnostic Testing (RIDT) during
hospitalization.
Hospitalization with Non-Influenza-CAP: A hospitalized
patient with CAP testing negative for an influenza virus of any
subtype using RT-PCR or RIDT during hospitalization.
Influenza Vaccine Status: Influenza vaccine status for the
influenza season of hospitalization was defined via self-report as
documented in the medical record.
Confounding Variables: The following variables were
considered as potentially confounding the relationship between
vaccine status and hospitalization with CAP: age, race, sex, and
history of the following social and medical factors: neoplastic
disease, congestive heart failure (CHF), renal disease, diabetes,
alcoholism, chronic obstructive pulmonary disease (COPD),
human immunodeficiency virus (HIV), and current smoking
status.

statistics: frequencies with percentages as well as medians with
interquartile ranges for categorical and continuous variables,
respectively. Statistical associations between variables were
made using Chi-Squared tests and Mann-Whitney U-tests.
P-values of less than 0.05 were considered statistically
significant. R version 3.4.3 (R Foundation, Vienna, Austria) was
used for all analyses [15].
Unadjusted and adjusted vaccine effectiveness estimates
were calculated. A crude Odds Ratio (cOR) evaluating the
unadjusted association between vaccine status and influenza/
non-influenza-CAP hospitalization was calculated from a 2x2
contingency table of observed influenza-CAP hospitalizations
by reported vaccination status. The unadjusted estimate was
calculated by the following equation, (1 – cOR) * 100 [16, 17].
To obtain adjusted vaccine effectiveness, a multivariable logistic
regression model was created to control for confounding effects
in the relationship between vaccine status and influenza/
non-influenza-CAP hospitalization. Based off of theoretical
importance, the final model controlled for age, sex, race,
neoplastic disease, CHF, renal disease, diabetes, alcoholism,
COPD, HIV, and current smoking status. The adjusted odds
ratio (aOR) was derived from this model and an adjusted
vaccine effectiveness estimate was calculated using the following
equation: (1 – aOR) * 100.
Post hoc sensitivity analysis included unadjusted and adjusted
vaccine effectiveness for hospitalizations with no influenza-CAP
coinfections, as well as sensitivity analysis for hospitalizations
that did not utilize RIDT.
Human Subjects Protection: Participants in the primary
University of Louisville Pneumonia Study provided their
consent for inclusion in the vaccine recall ancillary study.

Results
Characteristics of Vaccinated and Unvaccinated
Hospitalized Patients with and Without InfluenzaAssociated CAP
Table 1 outlines the characteristics of hospitalized patients
with CAP by vaccine status. Hospitalized CAP patients who
were vaccinated with the current year’s influenza vaccine were
significantly less likely to be from a Black/African American
racial background (16% vaccinated vs 22% unvaccinated,
P=0.002), were older (69 years vs 63 years P<0.001), smoked
less (26% vaccinated vs 36%, P<0.001) and were significantly
more likely to have various comorbid conditions.
A total of 1951 hospitalized patients with CAP were included
in analysis, and 831 (43%) reported having received the
influenza vaccination for the influenza season by the time
they were hospitalized. A total of 152 (8%) cases of influenzaCAP were confirmed in the study population, with 63 (8%)
cases confirmed in vaccinated individuals. There were 13 CAPinfluenza hospitalizations with a bacterial coinfection. Four of
these 13 coinfections were found in unvaccinated individuals.

Statistical Analysis: Comparisons between those with and
without influenza vaccination were made using descriptive
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Table 1 Patients Characteristics (n=1951)
Study Population
Total No. = 1951
Demographics
Male sex, Frequency(%)
Race: Black, Frequency(%)
Age, Median(IQR)*
Social and Medical History
Chronic obstructive pulmonary disease
Diabetes mellitus
Current smoker
Congestive heart failure
HIV disease
Stroke
Neoplastic disease
Renal disease
Obesity (BMI >= 30)
Severity of Disease on Admission
Need for intensive care
Altered mental status
Need for ventilatory support
Need for vasopressors
*IQR: Interquartile range

Unvaccinated
1120

Vaccinated
831

P-value

496 (44)
241 (22)
63 (18)

367 (44)
131 (16)
69 (16)
Frequency (%)
409 (49)
296 (36)
218 (26)
250 (30)
13 (2)
93 (11)
105 (13)
254 (31)
313 (38)
Frequency (%)
116 (14)
116 (14)
98 (12)
14 (2)

0.994
0.002
<0.001

492 (44)
326 (29)
402 (36)
265 (24)
35 (3)
106 (9)
105 (9)
279 (25)
408 (36)
178 (16)
163 (15)
133 (12)
23 (2)

0.023
0.003
<0.001
0.002
0.04
0.242
0.026
0.007
0.629
0.264
0.76
>0.999
0.672

Influenza Vaccine Effectiveness for Prevention of
Hospitalization due to Influenza-Associated CAP
Table 2 outlines the observed 2x2 Contingency Table for the
proportion of influenza-CAP hospitalization by vaccination
status. The unadjusted vaccine effectiveness was not significant,
with a point estimate of 5% (95% CI: [-33%, 32%]). After
adjusting for potential cofounders, vaccine effectiveness was
also not significant with a point estimate of 8% (95% CI: [-30%,
35%]).
Table 2 2x2 Contingency Table: Influenza-CAP Hospitalizations by
Vaccination Status
Non-Influenza-CAP
Influenza-CAP

Unvaccinated
1031 (A)
89 (C)

Vaccinated
768 (B)
63 (D)

Crude, Unadjusted Odds Ratio (𝒄𝒄𝒄𝒄𝒄𝒄)

= (𝐴𝐴/𝐶𝐶)/(𝐵𝐵/𝐷𝐷)
= (1031/89) / (768/63)
= 0.950272121 ≈ .95
Crude, Unadjusted Vaccine Effectiveness = (1 − 𝑐𝑐𝑐𝑐𝑐𝑐) ∗ 100
= (1 − .95) ∗ 100
= 5%

Post Hoc Sensitivity Analysis

The presence of coinfection was unlikely to alter the effectiveness
of the vaccine. This was confirmed by post hoc sensitivity
analysis in which the 13 CAP-influenza infections were removed
from analysis. With no adjustments, vaccine effectiveness
in hospitalizations with no CAP-influenza coinfections was
not significant and remained insignificant after adjusting for
potential cofounders. The type of influenza test used was also
considered for post hoc sensitivity analysis to control for the
effect of false-negative RIDT. Only hospitalizations who received
RT-PCR testing were included in this analysis. Unadjusted and
adjusted estimates were not significant. Post hoc sensitivity
analysis suggests that the influenza vaccine effectiveness in CAP
hospitalizations is not significantly affected by influenza-CAP
coinfections, or the type of influenza test conducted.

Discussion
This study suggests that the seasonal influenza vaccine may not
be effective for preventing hospitalizations due to influenzaCAP. One important clinical implication is that although
vaccines may be a primary prevention strategy for some
infections, they are not 100% effective. Populations at risk for
severe disease or poor clinical outcomes, such as the young

children and the elderly, may need to take increased measures to
reduce the risk of influenza infection. As vaccination remains as
the primary recommendation for prevention, clinicians should
also recommend annual vaccinations and monitor vaccination
status of all patients.
Our data contradicts the results of other studies from similar
years, and vaccine effectiveness reported by the CDC during
the 2014-2015 and 2015-2016 flu seasons. The CDC reports, in
reference to a 2015 study conducted by Zimmerman, R.K., et al.
[18], an adjusted vaccine effectiveness of 19% (95% CI: [10% 27%]) during the 2014-2015 flu season. This is significantly
higher than our suggested effectiveness in influenza-CAP
hospitalizations. For the 2015-2016 flu season, the CDC
reported an adjusted vaccine effectiveness from another of 48%
(95% CI [41% - 55%]) [19], which is significantly higher than
our suggested effectiveness in influenza-CAP hospitalizations.
Similar to our study, vaccine effectiveness was calculated from
the results of test-negative design from the same study years.
However, conflicting results are likely due to different study
populations. Reports from the CDC are based off of results from
studies across all age groups, while our study is only specific to
hospitalizations due to CAP.
It is possible that, although we did not find the vaccine to be
effective for the prevention of hospitalization due to influenzaCAP, it may be effective for other outcomes or prevention of
influenza infection. Previous vaccine studies have suggested
potential benefits of influenza vaccination other than preventing
CAP-hospitalization. In addition to reducing the risk of CAPhospitalizations, a 2005 cohort study of individuals 65 years
and older reported a reduced risk of all-cause mortality before,
during, and after flu seasons when comparing vaccinated and
unvaccinated individuals [20]. Results from this study are
likely due to the advantages in the study design, which were not
obtainable in our study. Jackson, L.A., et al. (2006), rigorously
followed members of a health maintenance organization
(HMO), prospectively recording information on enrollment,
immunizations, as well diagnosis in inpatient and outpatient
settings, allowing for the control of multiple biases, and the
assessment of multiple outcomes at different time periods.
Our study does provide supporting evidence that vaccine
effectiveness varies substantially from year to year and
evidence that findings from other studies may not estimate
the true effectiveness in hospitalizations from influenzaCAP. It should also be noted that vaccine studies often differ
in design and complexity, with no best standard or practice
currently recognized. A strength of this study is the use of data
from a population-based study, increasing the sample size and
potentially increasing generalizability. Additionally, using a
test-negative study design to estimate vaccine effectiveness
offered a real-world view on how well the influenza vaccine
reduced hospitalizations due to influenza-CAP and how well the
target population was immunized.
This study has several limitations. Although test-negative study
designs are generally simple and less costly, they are subject to
many forms of bias [10]. First, not all hospitalization records
reported the use of PCR diagnostics for influenza, which is a
standard for laboratory confirmation of influenza virus. Although
readily available and able to provide quick results, previous
studies have shown that the diagnostic accuracy of a RIDT
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can vary across populations [21]. Therefore, patients testing
negative on a RIDT and who did not receive a PCR test may have
been misclassified into the non-influenza-CAP hospitalization
group. It is also believed that for some vaccines, self-reported
vaccination status may not match actual vaccine receipt [22]
[23]. This would bias our results through misclassification of
the predictor and outcome variables. Although influenza vaccine
is recommended for individuals without contraindications over
the age of 6 months in the United States, actual vaccine receipt
is differentially distributed between individuals with different
characteristics and geographies. This may introduce bias by the
way of a form of confounding by indication, necessitating other
study designs or analytical approaches.
Another limitation is through the pooling of vaccine
effectiveness estimates across multiple study years. It is possible
that the vaccine may have been effective one year but not the
next, or vice versa, leading to an overall estimate that suggested
it was not effective. It is suggested that multi-season studies
may be a more useful approach when trying to understand
the effectiveness of repeat vaccination [24], which was not
considered in this study. It is also unknown which vaccine route
was obtained, potentially adding more bias to the study results.
During the time of this study, individuals were still receiving
Live-Attenuated Influenza Vaccine via nasal mist, which the
ACIP advised against using during the 2016 – 2017 flu season
due to identification of inferiority to other routes [25] . Further,
the population under study is generally older. Currently, elderly
individuals are recommended to receive high-dose influenza
vaccine to counteract age-related immunosenescence [26,
27]. We did not collect this data, which may result in some
bias in our estimates. Finally, since we did not collect data on
influenza subtypes, it is possible that the vaccine is effective for
various influenza A or influenza B strains in the prevention of
hospitalization for influenza-CAP.
Vaccine effectiveness estimates for various outcomes should
continue to be studied on an annual basis. Prospective studies
have the potential to evaluate other outcomes other than
hospitalization or infection. Potential mechanisms of interaction
may exist between vaccine uptake and outcomes such as severity
of disease, time to clinical improvement, length of hospital stay,
clinical failure, and short and long-term mortality. Additional
analytical approaches to counteract confounding by indication,
misclassification, and geographical variations in vaccine receipt
should be enhanced and utilized in future large-scale vaccine
effectiveness studies.
In conclusion, we found that, over the 2014/2015 and 2015/2016
influenza seasons, influenza vaccine was not effective for
prevention of hospitalization with influenza-CAP. Development
of novel vaccines that enhance effectiveness for various
outcomes, and are effective across multiple seasons, are needed.
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